What Is 5-Amino-1MQ?

5-Amino-1MQ stands for 5-amino-1-methylquinolinium. It is a small synthetic molecule classified as a cell-permeable NNMT inhibitor. NNMT is short for nicotinamide N-methyltransferase, an enzyme found in fat tissue, the liver, and several other organs. Despite being grouped with peptides in many online discussions, 5-Amino-1MQ is not a peptide. Peptides are chains of amino acids; 5-Amino-1MQ is a quinolinium salt, a completely different chemical class.

The compound was developed as a research tool to study what happens when NNMT activity is blocked. NNMT uses a methyl group from S-adenosylmethionine (SAM) to methylate nicotinamide, a form of vitamin B3. When researchers inhibit this enzyme, SAM and NAD-related metabolites accumulate in cells, which appears to shift how those cells handle energy. The compound's small size and cell-permeability make it useful for laboratory work because it can cross cell membranes without special delivery systems.

Vendors sell 5-Amino-1MQ as a research chemical intended for laboratory investigation. It has not been approved for human use by any regulatory authority, and it is not equivalent to any prescription drug or approved pharmaceutical product.

How Does NNMT Inhibition Work at the Cell Level?

NNMT is expressed at high levels in white adipose tissue, particularly in people with obesity. When NNMT is active, it consumes methyl groups from SAM and converts nicotinamide into 1-methylnicotinamide. This process draws down the cellular pool of SAM and, indirectly, NAD+ precursors. Researchers have hypothesized that high NNMT activity in fat tissue creates a metabolic environment that favors fat storage and reduces energy expenditure.

When 5-Amino-1MQ blocks NNMT, SAM levels in the cell rise. Higher SAM availability supports methylation reactions involved in gene regulation and metabolism. Separately, more nicotinamide stays available as a precursor for NAD+ synthesis. NAD+ is a coenzyme central to cellular energy metabolism and is also used by sirtuins, a family of proteins associated with metabolic regulation. In cell-culture experiments, this chain of events has been observed to reduce the differentiation of precursor cells into mature fat cells, a process called adipogenesis.

It is worth being precise about what this means. These are mechanistic observations from controlled laboratory conditions. Showing that a compound changes enzyme activity in a dish or in a mouse does not automatically predict the same effect in a human body, where thousands of other variables interact simultaneously.

What Does the Animal and Cell Research Show?

The most-cited study on 5-Amino-1MQ was published in 2021 in Cell Chemical Biology by Kannt and colleagues. In that study, mice fed a high-fat diet and treated with 5-Amino-1MQ showed reduced body weight gain and lower fat mass compared to untreated control mice. The treated animals also showed changes in adipose tissue gene expression consistent with reduced fat cell activity. This was a controlled animal study, not a human trial, and the results cannot be directly extrapolated to people.

Earlier foundational work on NNMT inhibition as a concept appeared in a 2013 paper in Nature by Kraus and colleagues, which used a different NNMT inhibitor in mice and reported reduced adiposity and improved metabolic markers. That study helped establish NNMT as a target of interest and informed later development of compounds like 5-Amino-1MQ. Again, this was animal research.

In cell-culture work, 5-Amino-1MQ has been shown to inhibit the differentiation of 3T3-L1 cells, a standard laboratory fat-cell model, into mature adipocytes. These in-vitro findings are useful for understanding mechanism but sit at the lowest tier of evidence for predicting human outcomes. No peer-reviewed human clinical trials on 5-Amino-1MQ have been published as of mid-2025.

  • 2021 Cell Chemical Biology mouse study: reduced weight gain and fat mass on high-fat diet
  • 2013 Nature mouse study: NNMT inhibition broadly linked to reduced adiposity (different inhibitor)
  • Cell-culture work: reduced fat cell differentiation in 3T3-L1 model
  • No published human RCTs or phase I/II trials identified

How Strong Is the Evidence, Honestly?

The evidence for 5-Amino-1MQ sits almost entirely at the preclinical tier, meaning animal studies and cell experiments. These are genuinely useful for generating hypotheses and understanding biology, but they are not sufficient to draw conclusions about whether the compound works in humans, at what exposures, or with what risks. The gap between a promising mouse study and a proven human therapy is wide, and most compounds that look good in animals do not replicate those results in human trials.

There are also no published long-term safety studies in animals, and no published human pharmacokinetic data showing how the compound is absorbed, distributed, or cleared in people. Without that data, questions about exposure levels, organ effects, and drug interactions remain open. Anyone reading vendor claims that go beyond what the published research supports should treat those claims with skepticism.

One additional complexity is that NNMT plays roles in multiple tissues beyond fat, including the liver, muscle, and brain. Inhibiting it systemically could have effects in those tissues that animal studies have not fully characterized. This is a normal part of early-stage research, not a reason to dismiss the science, but it is a reason to wait for more complete data before drawing firm conclusions.

Regulatory Status and Research Classification

5-Amino-1MQ is a research chemical. That classification means it is sold for laboratory and investigational use, not for human consumption or therapeutic application. No government health authority, including the FDA, has reviewed or authorized it for any medical purpose. It does not have a branded pharmaceutical form the way some other research-adjacent compounds do.

This is meaningfully different from compounds like semaglutide, where the branded drugs Ozempic and Wegovy have gone through full clinical trial programs and received regulatory approval for specific indications. Research chemicals like 5-Amino-1MQ have not completed that process. The distinction matters because regulatory review includes safety data, manufacturing standards, and efficacy evidence that simply does not exist yet for 5-Amino-1MQ.

ClinicalTrials.gov, the U.S. registry for human research studies, shows no registered trials for 5-Amino-1MQ as of mid-2025. That absence does not mean research will never happen, but it does mean the compound is at an early stage where human data collection has not formally begun under registered trial conditions.

Frequently asked questions

Is 5-Amino-1MQ the same thing as a peptide?

No. 5-Amino-1MQ is a quinolinium salt, a small synthetic organic molecule. Peptides are short chains of amino acids linked by peptide bonds. The two are chemically unrelated. The confusion likely comes from vendors and forums that group various research chemicals together under broad wellness categories.

Has 5-Amino-1MQ been tested in humans?

No published human clinical trials on 5-Amino-1MQ exist as of mid-2025. The available research consists of mouse studies and cell-culture experiments. ClinicalTrials.gov shows no registered trials for the compound. Human pharmacokinetic and safety data have not been published in peer-reviewed literature.

What is NNMT and why do researchers care about inhibiting it?

NNMT, or nicotinamide N-methyltransferase, is an enzyme that transfers a methyl group onto nicotinamide, consuming SAM in the process. It is highly expressed in fat tissue, especially in obesity. Researchers are interested in it because blocking it in animal models appears to raise SAM and NAD+ precursor levels in cells, which has been linked to reduced fat cell formation and changes in energy metabolism. Whether those effects translate to humans is still an open question.

Sources

  1. Kannt et al., 2021, Cell Chemical Biology Primary 5-Amino-1MQ mouse study
  2. Kraus et al., 2014, Nature Medicine Foundational NNMT inhibition mouse research
  3. Pissios, 2017, Trends in Endocrinology and Metabolism NNMT biology and metabolic relevance review

Educational and informational content only. This is not medical advice, diagnosis, or treatment. The compounds discussed are research compounds that are not approved for human use outside specific prescribed contexts. Always consult a qualified, licensed clinician before making any health decision.